West Pharmaceutical Services Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 23 April 2026: press release. Guidance figures: 5 raised, 5 new, 2 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Net sales grew 21% reported: Net sales were $844.9 million, up 21.0% on the prior-year quarter, with organic growth of 15.3%. Source
• Proprietary Products rose 23.3%: Proprietary Products net sales rose 23.3% to $694.3 million, with organic growth of 17.5%. Source
• HVP Components rose 29.6%: HVP Components sales were $409.3 million, 48% of company net sales, driven by Westar and NovaPure products. Source
• Adjusted operating margin reached 21.4%: Adjusted operating profit was $181.0 million, a 21.4% margin, against $125.0 million and 17.9% a year earlier. Source
• Free cash flow of $47.2 million: Operating cash flow was $89.9 million and capital expenditures were $42.7 million, against $129.4 million and $71.3 million a year earlier. Source
• Share repurchases of $297.6 million: Shares purchased under repurchase programs totaled $297.6 million in the quarter, against $133.5 million a year earlier, and 1.2 million shares were bought. Source
• SmartDose 3.5mL sale to AbbVie: The company recorded $1.9 million of charges in the quarter tied to its agreement to sell the SmartDose 3.5mL On-Body Delivery System and facilities to AbbVie. Source

“Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues.”

Eric M. Green, President, Chief Executive Officer and Chair of the Board

Guidance

What changed from last quarter

• Guidance raised: Full-year net sales guidance raised; figures are in the guidance list. Source
• Guidance raised: Full-year adjusted-diluted EPS guidance raised; figures are in the guidance list. Source
• Guidance kept: Full-year capital spending guidance left unchanged. Source
• New guidance: Second-quarter net sales and adjusted-diluted EPS guidance introduced for the first time. Source
• New: Contract-Manufactured Products segment renamed West Vantage, effective the first quarter of 2026. Source
• New: Share repurchase program announced in mid-February 2026, under which 1.2 million shares were bought in the quarter. Source

Quarter results and growth

• Net sales grew 21% reported: Net sales were $844.9 million, up 21.0% on the prior-year quarter, with organic growth of 15.3%. Source
• Diluted EPS rose 56%: Diluted EPS was $1.92 against $1.23 a year earlier, up 56.1%. Source
• Adjusted EPS rose 47%: Adjusted-diluted EPS was $2.13, up 46.9%. Adjusted figures exclude unallocated items such as restructuring charges. Operating cash flow was $89.9 million. Source

Segments and regions

• Proprietary Products rose 23.3%: Proprietary Products net sales rose 23.3% to $694.3 million, with organic growth of 17.5%. Source
• West Vantage rose 11.6%: West Vantage net sales rose 11.6% to $150.6 million, with 6.2% organic growth, driven by self-injection devices for obesity and diabetes. Source
• Europe led geographic growth: Europe, Middle East and Africa sales were $399.4 million, up 30.1% reported and 17.9% organic. Americas rose 10.8% organically; Asia Pacific rose 29.3%. Source

“The better-than-expected performance can be attributed to continued market demand and the team's outstanding efforts in ramping up production, especially in Europe.”

Eric M. Green, President, Chief Executive Officer and Chair of the Board

Products and market groups

• HVP Components rose 29.6%: HVP Components sales were $409.3 million, 48% of company net sales, driven by Westar and NovaPure products. Source
• Delivery devices grew on self-injection platforms: HVP Delivery Devices sales were $123.6 million, 15% of net sales, with 27.5% organic growth on self-injection device platforms and Daikyo Crystal Zenith. Source
• Standard Products nearly flat organically: Standard Products sales were $161.4 million, 19% of company net sales; reported growth of 6.7% compared with 0.5% organic growth. Source
• Biologics grew fastest by market group: Biologics sales were $354.5 million, up 31.6% reported and 25.9% organic. Pharma and Generics each rose 9.8% organically. Source

Costs, margins and pricing

• Gross margin rose to 35.1%: Gross profit was $296.4 million, a 35.1% margin against 33.2% a year earlier. Cost of goods and services sold was 65% of net sales, against 67%. Source
• Adjusted operating margin reached 21.4%: Adjusted operating profit was $181.0 million, a 21.4% margin, against $125.0 million and 17.9% a year earlier. Source
• SG&A rose to $99.5 million: Selling, general and administrative expenses were $99.5 million, 12% of net sales, against $88.0 million. Stock-based compensation expense was $6.6 million, against $1.3 million. Source
• Restructuring charges fell from prior year: Restructuring and other charges were $1.4 million in operating profit this quarter, against $17.8 million a year earlier, which included $16.4 million of severance and related costs under the January 2025 plan. Source
• One-time tax cost from entity restructuring: A one-time tax cost of $12.0 million was recorded for an internal legal entity restructuring in the first quarter. Income tax expense was $44.7 million. Source

“As a result of these excellent first quarter results and expected continued momentum in our business, we are increasing our full-year 2026 guidance.”

Eric M. Green, President, Chief Executive Officer and Chair of the Board

Cash, capital and shareholder returns

• Free cash flow of $47.2 million: Operating cash flow was $89.9 million and capital expenditures were $42.7 million, against $129.4 million and $71.3 million a year earlier. Source
• Share repurchases of $297.6 million: Shares purchased under repurchase programs totaled $297.6 million in the quarter, against $133.5 million a year earlier, and 1.2 million shares were bought. Source
• Cash balance fell after buybacks: Cash and equivalents ended at $521.4 million, down from $791.3 million at year-end. Shares outstanding were 70.9 million, against 72.0 million at year-end. Source
• Working capital absorbed cash: Changes in assets and liabilities used $102.9 million in operating cash flow. Accounts receivable rose to $685.6 million from $574.4 million at year-end. Source
• Dividends paid, debt unchanged: Dividend payments were $15.8 million. Long-term debt was unchanged at $202.8 million. Source

Strategy, portfolio and reporting changes

• SmartDose 3.5mL sale to AbbVie: The company recorded $1.9 million of charges in the quarter tied to its agreement to sell the SmartDose 3.5mL On-Body Delivery System and facilities to AbbVie. Source
• Segment renamed West Vantage: Contract-Manufactured Products became West Vantage. The company said the name change leaves segment composition and prior-period figures unchanged. Source
• Restructuring programs still running: Restructuring charges continue under two existing programs: the January 2025 plan and the 2024 plan to optimize the legal structure of the Company and its subsidiaries. Source

Coming up, as management said on 23 April 2026

• SmartDose sale closing assumed mid-year: Net sales guidance continues to assume the SmartDose 3.5mL sale to AbbVie closes at mid-year. Source

Figures management reported

Earlier plans management reported on

• Not stated: The prior release said positive momentum was expected to continue in 2026; the current release refers to expected continued momentum.
• Ahead: Management said first-quarter revenues and adjusted EPS exceeded expectations. Source

Other quarters

• Q2 FY2026 earnings call
• Q4 FY2025 earnings call
• Q3 FY2025 earnings call
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.